<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Contemp Oncol (Pozn)</journal-id><journal-id journal-id-type="iso-abbrev">Contemp Oncol (Pozn)</journal-id><journal-id journal-id-type="publisher-id">WO</journal-id><journal-title-group><journal-title>Contemporary Oncology</journal-title></journal-title-group><issn pub-type="ppub">1428-2526</issn><issn pub-type="epub">1897-4309</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26843843</article-id><article-id pub-id-type="pmc">4731452</article-id><article-id pub-id-type="publisher-id">26449</article-id><article-id pub-id-type="doi">10.5114/wo.2015.56652</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Rodr&#x000ed;guez</surname><given-names>Gabriel</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Aranda-Moreno</surname><given-names>Catalina</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Olivares-Corichi</surname><given-names>Ivonne M.</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Garcia-Sanchez</surname><given-names>Jose R.</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Hospital General Regional No. 72 IMSS. Estado de M&#x000e9;xico, M&#x000e9;xico</aff><aff id="AF0002"><label>2</label>Escuela Superior de Medicina del Instituto Polit&#x000e9;cnico Nacional, M&#x000e9;xico</aff><author-notes><corresp id="cor1"><bold>Address for correspondence: Jose R. Garcia Sanchez</bold>, Escuela Superior de Medicina, del Instituto Politecnico Nacional. <email xlink:href="jrgarcias@ipn.mx">jrgarcias@ipn.mx</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>19</volume><issue>6</issue><fpage>462</fpage><lpage>466</lpage><history><date date-type="received"><day>15</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Termedia</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="st1"><title>Aim of the study</title><p>In breast cancer, oestrogen receptor (ER), progesterone receptor (PgR), and HER2 (HER2/Neu) expression status are used to classify neoplasms into subtypes: Luminal A, Luminal B, HER2/Neu type, and Basallike. The aim of the present study was to establish the molecular subtypes of breast cancers and their association with tumour characteristics and reproductive factors in Mexican women.</p></sec><sec id="st2"><title>Material and methods</title><p>A total of 1326 biopsies of breast tumour tissues were analysed for ER, PR, and HER2/Neu by immunohistochemistry (IHC). Information regarding age, tumour characteristics, and node involvement profiles were collected.</p></sec><sec id="st3"><title>Results</title><p>IHC established that the most common subtype of breast cancer was Luminal A (64.93%), followed by Basal-Like (13.88%), Luminal B (12.52%), and HER2/Neu (8.67%). T2-size tumours (&#x0003e; 2 cm but &#x0003c; 5 cm) were present in 47.59% of all patients. Univariate analysis showed that lymph node positivity (<italic>p</italic> = 0.009), stage (<italic>p</italic> = 0.013), and placement of the tumour (<italic>p</italic> = 0.001) were factors associated with breast cancer subtype.</p></sec><sec id="st4"><title>Conclusions</title><p>Our data show that IHC is useful for distinguishing different subtypes of breast cancer and that Luminal A is the most common breast cancer subtype in the Mexican population. All subtypes were associated with unfavourable clinicopathological features, suggesting that late diagnosis is an important contributor to high mortality rates in the Mexican population.</p></sec></abstract><kwd-group><kwd>breast cancer</kwd><kwd>immunohistochemistry</kwd><kwd>estrogen receptor</kwd><kwd>progesterone receptor</kwd><kwd>HER2</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Breast cancer (BC) is the main cause of death in women worldwide. In Mexico, BC is the primary cause of deaths related to neoplasia in women [<xref rid="CIT0001" ref-type="bibr">1</xref>]. BC represents a group of tumours that display biological behaviour complicated by diverse clinical variability. Histological classification is an important criterion used to determine a prognosis and the most effective treatment for the patient [<xref rid="CIT0002" ref-type="bibr">2</xref>&#x02013;<xref rid="CIT0005" ref-type="bibr">5</xref>]. For example, chemotherapy is commonly used for patients with high Ki-67 values, while endocrine therapy is used for ER+ tumours, and anti-HER2 (trastuzumab) therapy is used for HER2 (+) tumours [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Furthermore, decisions regarding the use of post-operative adjuvant treatment in recurrent cases are generally based on the ER and HER2 status of the primary tumour and the disease-free interval, recurrence site, and the performance status of the patient [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Currently, immunohistochemistry (IHC) is used to classify breast cancer based on the presence or absence of expression of oestrogen receptors (ER+ and ER&#x02013;). Two subtypes of ER+ tumours have been identified: luminal A (ER+ and/or PgR(+/&#x02013;), Her2&#x02013;) and luminal B (ER+, PgR(+/&#x02013;), Her2+), in addition to two subtypes of ER- tumours: HER2/Neu (ER-, PgR&#x02013;, Her2+), and Basal-like (ER&#x02013;, PgR&#x02013;, Her2&#x02013;). While other classifications based on gene expression profiling have also been used to classify breast cancer, the use of this technology in hospitals is currently limited, and assessments are made difficult by the use of paraffin samples [<xref rid="CIT0008" ref-type="bibr">8</xref>&#x02013;<xref rid="CIT0011" ref-type="bibr">11</xref>].</p><p>In Mexico, most health centres routinely use these biomarkers (ER, PR, and HER2) and IHC to make clinical determinations. However, there are few reports documenting which breast cancer subtypes are detected by each of these biomarkers [<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>]. In the present study, we estimated the prevalence of these biomarkers in breast cancer subtypes and identified associations between reproductive factors and risk for particular subtypes of breast cancer.</p></sec><sec sec-type="material|methods" id="S0002"><title>Material and methods</title><sec id="S20003"><title>Study population</title><p>Tlalnepantla de Baz is located in the north of the state of Mexico; its population is about 664,225 (85% urban and 15% rural). Cancer cases are diagnosed in different hospitals, clinics, and pathology labs throughout of the state of Mexico, and represent only 60% of the population. Regional incidence in 2013 was 8.2 per 100,000 women of 25 years old or more.</p></sec><sec id="S20004"><title>Patients</title><p>The protocol was approved by the Human Ethics and Research Committee at Hospital Regional No. 72 of the Mexican Institute for Social Security. All patients involved in the study signed an informed consent waiver. The study was conducted in accordance with the ethical principles described in the Declaration of Helsinki of 1975, as revised in 1983. The study was also consistent with Good Clinical Practice Guidelines. We assayed 1326 patients who were diagnosed with breast cancer from January 2007 to December 2011 at Hospital Regional No. 72 in the Mexican Institute for Social Security. Clinical information was retrieved from patient medical records, and slides containing biopsies of breast tumour tissues were used to analyse the selected receptors by IHC.</p></sec><sec id="S20005"><title>Immunohistochemistry</title><p>Biopsies of breast tumour tissues were obtained, fixed in formalin overnight, and embedded in paraffin. Heat-induced epitope retrieval was performed with sections treated with 0.1 M sodium citrate at pH = 6.2 (for PR and HER2) or EDTA buffer at pH = 9 (for ER) for 5 minutes in a microwave and incubated for 20 minutes at room temperature. Samples were then treated with hydroxide peroxide (0.3%) for 5 minutes and with blocking agent (1% BSA in PBS) for 1 hour prior to incubation with a monoclonal primary antibody against ER (SP1, Lab Vision, Fremont, CA, USA), PgR (PgR636, Lab Vision Fremont, CA, USA) or HER2/neu (A0185, Dako, Carpenteria, CA, USA) overnight at 4&#x000b0;C. Samples were then treated with Link reagent for 1 hour and streptavidin for another hour (Labelled streptavidin-biotin, Dako Corporation, Carpenter&#x000ed;a, CA, USA). Finally the slides were treated with diaminobenzidine to visualise ER&#x02013;, PgR&#x02013;, or HER2/neu-positive cells. After washing with tap water, sections were counterstained with Mayer's haematoxylin, dehydrated, and mounted.</p><p>The four most frequently used classifications were used to analyse IHC results: Luminal A (ER+ and/or PgR(+/&#x02013;), Her2&#x02013;), luminal B (ER+, PgR(+/&#x02013;), Her2+), HER2/Neu: ER&#x02013;, PgR&#x02013;, Her2+, and basal-like (ER&#x02013;, PR&#x02013;, Her2&#x02013;). Positive controls were included in each staining run and consisted of breast cancers known to express each of the antigens of interest. Cases were considered positive for ER and PgR when &#x0003e; 5% and &#x0003e;10% of the cells showed expression, respectively. Her2/neu evaluation was performed using the Herceptest<sup>&#x000ae;</sup> DAKO system, and were scored as follows. Score 0 and 1 = negative: when no immunoreaction occurred or less than 10% of the cells showed a diffuse immunoreaction. Score 2+ = positive: a low level of positive signal in the complete membrane in 10% of the cells. Score 3+ = positive: overexpression, indicated by strong immunoreactivity in the membrane in more than 10% of cells. Clinical information was retrieved from patient medical records for risk factors including menopause status, early menarche, late menopause, nulligravida, late pregnancy, and use of hormonal contraceptives. Information regarding other factors was also obtained, including tumour characteristics, the quadrant and side affected, the presence of metastatic axillary nodes, and whether surgery was performed.</p></sec><sec id="S20006"><title>Statistical analysis</title><p>All statistical analyses were performed using SPSS version 22. Pearson's &#x003c7;<sup>2</sup> test was used to investigate associations between categorical variables. A <italic>p</italic>-value of less than 0.05 (<italic>p</italic> &#x0003c; 0.05) was considered statistically significant.</p></sec></sec><sec sec-type="results" id="S0007"><title>Results</title><sec id="S20008"><title>Patients, clinicopathological features, and breast cancer subtypes</title><p>The study included 1326 patients diagnosed with breast cancer. The clinicopathological features of patients included in the study are shown in <xref ref-type="table" rid="T0001">Table 1</xref>. Nearly the same percentage of patients were premenopausal as were postmenopausal. Most carcinomas were intermediate stage (70%), high grade (21%), and had a high association with positive nodal status (64%). Approximately 47.59% of tumours were between 2 and 5 cm, and 22.1% were larger (<xref ref-type="table" rid="T0001">Table 1</xref>). Most tumours were ER positive (67.5%), while a smaller percentage were Her2/neu negative (21%). Patients were classified according to assessments of positive immunoreactivity for oestrogen receptor, progesterone receptor, and HER2/Neu. <xref ref-type="table" rid="T0002">Table 2</xref> shows the age at diagnosis and the classification obtained. The IHC study showed that Luminal A (64.93%) was the most common subtype, followed by Basal-like (13.88%), Luminal B (12.52%), and HER2/Neu (8.67%). The highest percentage of patients were aged 40&#x02013;69 years (<xref ref-type="table" rid="T0002">Table 2</xref>).
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Clinicopathologic features of the study population and immunohistochemical staining results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Clinicopathologic features</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">1326</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years), mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">53 &#x000b1;11</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Premenopausal</td><td align="center" rowspan="1" colspan="1">692</td><td align="center" rowspan="1" colspan="1">52.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Postmenopausal</td><td align="center" rowspan="1" colspan="1">634</td><td align="center" rowspan="1" colspan="1">47.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage<break/>&#x02003;I<break/>&#x02003;II<break/>&#x02003;III</td><td align="center" rowspan="1" colspan="1">
<break/>119<break/>936<break/>281</td><td align="center" rowspan="1" colspan="1">
<break/>9<break/>70<break/>21</td></tr><tr><td align="left" rowspan="1" colspan="1">Nodal status<break/>&#x02003;negative<break/>&#x02003;positive</td><td align="center" rowspan="1" colspan="1">
<break/>477<break/>849</td><td align="center" rowspan="1" colspan="1">
<break/>36<break/>64</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor size<break/>&#x02003;T1 (&#x0003c; 2 cm)<break/>&#x02003;T2 (2&#x02013;5 cm)<break/>&#x02003;T3 (&#x0003e; 5 cm)</td><td align="center" rowspan="1" colspan="1">
<break/>402<break/>631<break/>293</td><td align="center" rowspan="1" colspan="1">
<break/>30.32<break/>47.59<break/>22.1</td></tr><tr><td align="left" rowspan="1" colspan="1">ER status<break/>&#x02003;positive<break/>&#x02003;negative</td><td align="center" rowspan="1" colspan="1">
<break/>1013<break/>313</td><td align="center" rowspan="1" colspan="1">
<break/>76.4<break/>23.6</td></tr><tr><td align="left" rowspan="1" colspan="1">PR status<break/>&#x02003;Positive<break/>&#x02003;Negative</td><td align="center" rowspan="1" colspan="1">
<break/>896<break/>430</td><td align="center" rowspan="1" colspan="1">
<break/>67.5<break/>32.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Her2/neu status<break/>&#x02003;positive<break/>&#x02003;negative</td><td align="center" rowspan="1" colspan="1">
<break/>281<break/>1045</td><td align="center" rowspan="1" colspan="1">
<break/>21<break/>79</td></tr></tbody></table></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Tumour subtypes detected in Mexican women and classified by age group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Age range</th><th align="center" colspan="2" rowspan="1">Luminal A</th><th align="center" colspan="2" rowspan="1">Luminal B</th><th align="center" colspan="2" rowspan="1">HER2/Neu</th><th align="center" colspan="2" rowspan="1">Basal like</th><th align="center" colspan="2" rowspan="1">Total</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">30&#x02013;39</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">8.07</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">167</td><td align="center" rowspan="1" colspan="1">12.59</td></tr><tr><td align="left" rowspan="1" colspan="1">40&#x02013;49</td><td align="center" rowspan="1" colspan="1">211</td><td align="center" rowspan="1" colspan="1">15.91</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">4.75</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">2.41</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">3.92</td><td align="center" rowspan="1" colspan="1">358</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">50&#x02013;59</td><td align="center" rowspan="1" colspan="1">279</td><td align="center" rowspan="1" colspan="1">21.04</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">2.11</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">3.09</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">4.83</td><td align="center" rowspan="1" colspan="1">412</td><td align="center" rowspan="1" colspan="1">31.07</td></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;69</td><td align="center" rowspan="1" colspan="1">174</td><td align="center" rowspan="1" colspan="1">13.12</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">3.24</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.90</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">2.11</td><td align="center" rowspan="1" colspan="1">257</td><td align="center" rowspan="1" colspan="1">19.38</td></tr><tr><td align="left" rowspan="1" colspan="1">70&#x02013;79</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">4.83</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">1.36</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0.30</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">1.36</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">7.84</td></tr><tr><td align="left" rowspan="1" colspan="1">80&#x02013;89</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">1.96</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">2.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">861</td><td align="center" rowspan="1" colspan="1">64.93</td><td align="center" rowspan="1" colspan="1">166</td><td align="center" rowspan="1" colspan="1">12.52</td><td align="center" rowspan="1" colspan="1">115</td><td align="center" rowspan="1" colspan="1">8.67</td><td align="center" rowspan="1" colspan="1">184</td><td align="center" rowspan="1" colspan="1">13.88</td><td align="center" rowspan="1" colspan="1">1326</td><td align="center" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p>n &#x02013; number of patients, % &#x02013; percentage of patients</p></fn></table-wrap-foot></table-wrap></sec><sec id="S20009"><title>Tumour size in subtypes of breast cancer</title><p>With respect to tumour size, T2 was the most prevalent (&#x0003e; 2 cm but &#x0003c; 5 cm), with 47% of all patients scored as T2. The Luminal A subtype was observed in the highest percentage of these patients (65%) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>).</p><fig id="F0001" position="float"><label>Fig. 1</label><caption><p>Distribution of breast cancer subtypes by tumor size</p></caption><graphic xlink:href="WO-19-26449-g001"/></fig><p>Interestingly, in the Basal-like and HER2/Neu subtypes (the two subtypes with highest mortality), 7% and 4% of the patients, respectively, had T2 tumours and 3% of the patients in both subtypes had T3 (&#x0003e; 5 cm) tumours (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). These data show that in each breast cancer subtype, the majority of patients present unfavourable tumour size characteristics.</p></sec><sec id="S20010"><title>Relationship between breast cancer subtype, biological parameters, and reproductive factors</title><p>A statistical analysis was performed to explore the relationship between breast cancer subtypes and several factors, including positivity in the axillary lymph node, and the stage, side, and placement of the tumour. As shown in <xref ref-type="table" rid="T0003">Table 3</xref>, &#x003c7;<sup>2</sup> analysis revealed a significant association between breast cancer subtype and positivity in the lymph nodes, stage, and placement. In this context, luminal A patients displayed the highest axillary lymph node status, but not Basal like, luminal B, and HER2/Neu patients (39.44% vs. 9.5%, 8.8%, 6.18%, respectively). Similar behaviour was observed between these subtypes and stage II (45.78% vs. 9.43%, 9.58%, 5.81%) (<italic>p</italic> = 0.009). These data support the hypothesis that a late detection of this pathology is an important factor that could explain the high mortality in the Mexican population in this disease.
</p><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Association of clinical parameters with breast cancer subtype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Luminal A</th><th align="center" colspan="2" rowspan="1">Basal like</th><th align="center" colspan="2" rowspan="1">Luminal B</th><th align="center" colspan="2" rowspan="1">HER2/Neu</th><th align="center" rowspan="1" colspan="1">Patients (%)</th><th align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TF0001">*</xref><italic>p</italic> value</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Lymph node</bold><break/>&#x02003;negative<break/>&#x02003;positive</td><td align="center" rowspan="1" colspan="1">
<break/>338<break/>523</td><td align="center" rowspan="1" colspan="1">
<break/>25.49<break/>39.44</td><td align="center" rowspan="1" colspan="1">
<break/>57<break/>127</td><td align="center" rowspan="1" colspan="1">
<break/>4.30<break/>9.58</td><td align="center" rowspan="1" colspan="1">
<break/>49<break/>117</td><td align="center" rowspan="1" colspan="1">
<break/>3.70<break/>8.82</td><td align="center" rowspan="1" colspan="1">
<break/>33<break/>82</td><td align="center" rowspan="1" colspan="1">
<break/>2.49<break/>6.18</td><td align="center" rowspan="1" colspan="1">
<break/>477 (35.97%)<break/>849 (64.03%)</td><td align="left" rowspan="1" colspan="1">0.009<xref ref-type="table-fn" rid="TF0001">*</xref><break/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage</bold>
<break/>&#x02003;I<break/>&#x02003;II<break/>&#x02003;III</td><td align="center" rowspan="1" colspan="1">88<break/>607<break/>166</td><td align="center" rowspan="1" colspan="1">6.64<break/>45.78<break/>12.52</td><td align="center" rowspan="1" colspan="1">16<break/>125<break/>43</td><td align="center" rowspan="1" colspan="1">1.21<break/>9.43<break/>3.24</td><td align="center" rowspan="1" colspan="1">13<break/>127<break/>36</td><td align="center" rowspan="1" colspan="1">0.98<break/>9.58<break/>2.71</td><td align="center" rowspan="1" colspan="1">2<break/>77<break/>36</td><td align="center" rowspan="1" colspan="1">0.15<break/>5.81<break/>2.71</td><td align="center" rowspan="1" colspan="1">119 (8.97%)<break/>936 (70.59%)<break/>281 (21.19%)</td><td align="left" rowspan="1" colspan="1">0.010<xref ref-type="table-fn" rid="TF0001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Side</bold>
<break/>&#x02003;right<break/>&#x02003;left</td><td align="center" rowspan="1" colspan="1">
<break/>479<break/>382</td><td align="center" rowspan="1" colspan="1">
<break/>36.12<break/>28.81</td><td align="center" rowspan="1" colspan="1">
<break/>96<break/>88</td><td align="center" rowspan="1" colspan="1">
<break/>7.24<break/>6.64</td><td align="center" rowspan="1" colspan="1">
<break/>83<break/>83</td><td align="center" rowspan="1" colspan="1">
<break/>6.26<break/>6.26</td><td align="center" rowspan="1" colspan="1">
<break/>61<break/>54</td><td align="center" rowspan="1" colspan="1">
<break/>4.60<break/>4.07</td><td align="center" rowspan="1" colspan="1">
<break/>719 (54.22%)<break/>607 (45.78%)</td><td align="left" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Place</bold>
<break/>&#x02003;UOQ<break/>&#x02003;UIQ<break/>&#x02003;LOQCII<break/>&#x02003;central</td><td align="center" rowspan="1" colspan="1">
<break/>563<break/>90<break/>18<break/>30<break/>160</td><td align="center" rowspan="1" colspan="1">
<break/>42.46<break/>6.79<break/>1.36<break/>2.26<break/>12.07</td><td align="center" rowspan="1" colspan="1">
<break/>144<break/>11<break/>2<break/>8<break/>19</td><td align="center" rowspan="1" colspan="1">
<break/>10.86<break/>0.83<break/>0.15<break/>0.60<break/>1.43</td><td align="center" rowspan="1" colspan="1">
<break/>102<break/>20<break/>8<break/>6<break/>30</td><td align="center" rowspan="1" colspan="1">
<break/>7.69<break/>1.51<break/>0.60<break/>0.45<break/>2.26</td><td align="center" rowspan="1" colspan="1">
<break/>65<break/>10<break/>8<break/>4<break/>28</td><td align="center" rowspan="1" colspan="1">
<break/>4.90<break/>0.75<break/>0.60<break/>0.30<break/>2.11</td><td align="center" rowspan="1" colspan="1">
<break/>874 (65.91%)<break/>131 (9.88%)<break/>36 (2.71%)<break/>48 (3.62%)<break/>237 (17.7%)</td><td align="left" rowspan="1" colspan="1">
<break/>0.001<xref ref-type="table-fn" rid="TF0001">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p>n &#x02013; number of patients, % &#x02013; percentage of patients, UOQ &#x02013; upper outer quadrant, UIQ &#x02013; upper inner quadrant, LOQ &#x02013; lower outer quadrant, LIQ &#x02013; lower inner quadrant.</p></fn><fn id="TF0001"><label>*</label><p>p &#x02264; 0.01 was considered as statistically significant</p></fn></table-wrap-foot></table-wrap><p>In contrast, there was not a significant association between subtypes and side (<xref ref-type="table" rid="T0003">Table 3</xref>).</p><p>Because a large amount of evidence links breast cancer with reproductive factors, different parameters related to these factors were analysed [menopause status, late menopause (age &#x02265; 54 years), early menarche (age &#x02264; 11 years), late pregnancy (age &#x02265; 31 years), and nulligravida]. No significant association was observed between breast cancer subtypes and parameters related to reproductive factors (<xref ref-type="table" rid="T0004">Table 4</xref>). Interestingly, the use of oral contraceptives was the only parameter that showed an association with subtypes of breast cancer (<xref ref-type="table" rid="T0004">Table 4</xref>).
</p><table-wrap id="T0004" position="float"><label>Table 4</label><caption><p>Association of hormonal state with breast cancer subtype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Luminal A<break/>Patients<break/>861</th><th align="center" rowspan="1" colspan="1">Basal like<break/>Patients<break/>184</th><th align="center" rowspan="1" colspan="1">Luminal B<break/>Patients<break/>166</th><th align="center" rowspan="1" colspan="1">HER2/Neu<break/>Patients<break/>115</th><th align="center" valign="top" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="TF0002">*</xref><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Menopause status</bold>
<break/>&#x02003;pre<break/>&#x02003;post</td><td align="center" rowspan="1" colspan="1">
<break/>433<break/>428</td><td align="center" rowspan="1" colspan="1">
<break/>94<break/>90</td><td align="center" rowspan="1" colspan="1">
<break/>98<break/>68</td><td align="center" rowspan="1" colspan="1">
<break/>67<break/>48</td><td align="center" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Late Menopause</bold>
<break/>&#x02003;Yes<break/>&#x02003;not</td><td align="center" rowspan="1" colspan="1">
<break/>229<break/>632</td><td align="center" rowspan="1" colspan="1">
<break/>38<break/>146</td><td align="center" rowspan="1" colspan="1">
<break/>44<break/>122</td><td align="center" rowspan="1" colspan="1">
<break/>29<break/>86</td><td align="center" rowspan="1" colspan="1">0.409</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Menarche</bold>
<break/>&#x02003;Yes<break/>&#x02003;not</td><td align="center" rowspan="1" colspan="1">
<break/>135<break/>726</td><td align="center" rowspan="1" colspan="1">
<break/>34<break/>150</td><td align="center" rowspan="1" colspan="1">
<break/>20<break/>146</td><td align="center" rowspan="1" colspan="1">
<break/>15<break/>100</td><td align="center" rowspan="1" colspan="1">0.346</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Late pregnancy</bold>
<break/>&#x02003;Yes<break/>&#x02003;not</td><td align="center" rowspan="1" colspan="1">
<break/>163<break/>698</td><td align="center" rowspan="1" colspan="1">
<break/>30<break/>154</td><td align="center" rowspan="1" colspan="1">
<break/>22<break/>144</td><td align="center" rowspan="1" colspan="1">
<break/>19<break/>96</td><td align="center" rowspan="1" colspan="1">0.319</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nulligravida</bold>
<break/>&#x02003;yes<break/>&#x02003;not</td><td align="center" rowspan="1" colspan="1">
<break/>97<break/>764</td><td align="center" rowspan="1" colspan="1">
<break/>21<break/>163</td><td align="center" rowspan="1" colspan="1">
<break/>11<break/>155</td><td align="center" rowspan="1" colspan="1">
<break/>15<break/>100</td><td align="center" rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Oral contraceptive</bold>
<break/>&#x02003;yes<break/>&#x02003;not</td><td align="center" rowspan="1" colspan="1">
<break/>144<break/>717</td><td align="center" rowspan="1" colspan="1">
<break/>32<break/>152</td><td align="center" rowspan="1" colspan="1">
<break/>21<break/>145</td><td align="center" rowspan="1" colspan="1">
<break/>9<break/>106</td><td align="center" rowspan="1" colspan="1">0.050<xref ref-type="table-fn" rid="TF0002">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TF0002"><label>*</label><p>p &#x02264; 0.05 was considered as statistically significant</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="S0011"><title>Discussion</title><p>BC is a major cause of morbidity and mortality in women worldwide. However, evidence indicates that more of 55% of new cases occur in developing countries [<xref rid="CIT0014" ref-type="bibr">14</xref>]. In Mexico, BC is a public health problem because it is the main cause of death by malignant tumours in women of reproductive age [<xref rid="CIT0001" ref-type="bibr">1</xref>]. In this study, we observed that BC was often detected before of 50 years of age, similar to what has been reported by other authors in the Mexican population [<xref rid="CIT0015" ref-type="bibr">15</xref>, <xref rid="CIT0016" ref-type="bibr">16</xref>]. This observation confirms that this pathology is detected in Mexican women a decade before the normal age of onset in other countries [<xref rid="CIT0017" ref-type="bibr">17</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>]. This study also shows the importance of using biological markers to classify pathologies and to make decisions when treating patients. In this context, this study shows, using an analysis of ER, PR, and Her-2/Neu immunoreactivity in tumour biopsies, that Luminal A is the most common breast cancer subtype in our study population, followed by Basal-like, Luminal B, and HER2/Neu as the less common. Although these data show that 77.5% of patients (classified as luminal A and B) can be treated with ER inhibitors (tamoxifen) or aromatase inhibitors, the association established between these subtypes of tumours and unfavourable characteristics indicate that the late detection of these pathologies in our population is an important factor that probably reduces the success of treatments for this disease.</p><p>Basal-like and HER2/Neu breast cancer subtypes have higher mortality rates than the other subtypes in this study and were associated with unfavourable tumour characteristics, suggesting that the high mortality rate for these tumour types could also be related to late diagnosis.</p><p>Several studies have reported that ovarian hormones (oestrogens) and reproductive patterns play an important role in the development of breast cancer [<xref rid="CIT0019" ref-type="bibr">19</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>]. However, our study showed no association between breast cancer subtypes and risk factors that have been described in other populations [<xref rid="CIT0021" ref-type="bibr">21</xref>], with the exception of the use of oral contraceptives (<xref ref-type="table" rid="T0004">Table 4</xref>). These findings suggest that the association between menstrual and reproductive factors with the development of breast cancer may differ in our study population and that these risk factors do not contribute to the incidence and mortality rate of this pathology in the study population.</p><p>In this study, we used a classification system based on the immunohistochemical detection of biological markers (ER, PR, and HER2/Neu). While the use of these biomarkers plays an important role in diagnostic and clinical practice and the guidance of endocrine therapy, very few studies have been reported in our study population. The tumour classifications identified in this study were comparable to studies performed in other countries [<xref rid="CIT0022" ref-type="bibr">22</xref>, <xref rid="CIT0023" ref-type="bibr">23</xref>]. However, our data show that the use of these biomarkers allows a definition of the type of breast cancer, which may be useful when selecting the best treatment or when establishing which patients have a higher risk of secondary effects from cytotoxic treatments.</p><p>In conclusion, this study describes the subtypes of breast cancer most frequently detected in Mexican women and establishes an association in this population between breast cancer and biological parameters and hormonal state. This classification provides a system for defining breast cancer and supports the use of these biomarkers in the determination of diagnosis and prognosis in these patients.</p></sec></body><back><sec><title/><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knaul</surname><given-names>FM</given-names></name><name><surname>Lopez Carrillo</surname><given-names>L</given-names></name><name><surname>Lazcano Ponce</surname><given-names>E</given-names></name><name><surname>Gomez Dantes</surname><given-names>H</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Torres</surname><given-names>G</given-names></name></person-group><article-title>Breast cancer: a challenge for society and health systems</article-title><source>Salud Publica Mex</source><year>2009</year><volume>51</volume><issue>Suppl 2</issue><fpage>s138</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19967267</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blows</surname><given-names>FM</given-names></name><name><surname>Driver</surname><given-names>KE</given-names></name><name><surname>Schmidt</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><fpage>e1000279</fpage><pub-id pub-id-type="pmid">20520800</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheang</surname><given-names>MC</given-names></name><name><surname>Chia</surname><given-names>SK</given-names></name><name><surname>Voduc</surname><given-names>D</given-names></name><etal/></person-group><article-title>Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer</article-title><source>J Natl Cancer Inst</source><year>2009</year><volume>101</volume><fpage>736</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19436038</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugh</surname><given-names>J</given-names></name><name><surname>Hanson</surname><given-names>J</given-names></name><name><surname>Cheang</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>1168</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">19204205</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Hsu</surname><given-names>FD</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5367</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15328174</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Thurlimann</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name></person-group><article-title>Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>1319</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">19535820</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hortobagyi</surname><given-names>GN</given-names></name></person-group><article-title>Treatment of breast cancer</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><fpage>974</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">9753714</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name></person-group><article-title>Basal breast cancer: a complex and deadly molecular subtype</article-title><source>Curr Mol Med</source><year>2012</year><volume>12</volume><fpage>96</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">22082486</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertucci</surname><given-names>F</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Maraninchi</surname><given-names>D</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name></person-group><article-title>Gene expression profiling and clinical outcome in breast cancer</article-title><source>Omics</source><year>2006</year><volume>10</volume><fpage>429</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">17233555</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Bertoli</surname><given-names>G</given-names></name><name><surname>Ripamonti</surname><given-names>M</given-names></name><name><surname>Mauri</surname><given-names>G</given-names></name><name><surname>Zoppis</surname><given-names>I</given-names></name><name><surname>Rosa</surname><given-names>PA</given-names></name><name><surname>Gilardi</surname><given-names>MC</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name></person-group><article-title>Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition</article-title><source>PloS One</source><year>2014</year><volume>9</volume><fpage>e97681</fpage><pub-id pub-id-type="pmid">24866763</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name></person-group><article-title>Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>545</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17585334</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>P</given-names></name><name><surname>Rivadeneyra</surname><given-names>J</given-names></name><name><surname>Rabago</surname><given-names>M</given-names></name><name><surname>Guzman-Patraca</surname><given-names>C</given-names></name></person-group><article-title>Estrogen receptors in human breast cancer in Mexican patients</article-title><source>Arch Invest Med (Mex)</source><year>1980</year><volume>11</volume><fpage>303</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">7425781</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>ME</given-names></name><name><surname>Wertheim</surname><given-names>BC</given-names></name><name><surname>Natarajan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2013</year><volume>22</volume><fpage>1853</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23950213</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>P</given-names></name></person-group><article-title>&#x0201c;Westernizing&#x0201d; women's risks? Breast cancer in lower-income countries</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>213</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18199859</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderon-Garciduenas</surname><given-names>AL</given-names></name><name><surname>Sanabria-Mondragon</surname><given-names>M</given-names></name><name><surname>Hernandez-Beltran</surname><given-names>L</given-names></name><name><surname>Lopez-Amador</surname><given-names>N</given-names></name><name><surname>Cerda-Flores</surname><given-names>RM</given-names></name></person-group><article-title>Mammographic breast density patterns in asymptomatic mexican women</article-title><source>Radiol Res Pract</source><year>2012</year><volume>2012</volume><fpage>127485</fpage><pub-id pub-id-type="pmid">23346398</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Cuevas</surname><given-names>S</given-names></name><name><surname>Macias</surname><given-names>CG</given-names></name><name><surname>Franceschi</surname><given-names>D</given-names></name><name><surname>Labastida</surname><given-names>S</given-names></name></person-group><article-title>Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries</article-title><source>Cancer</source><year>2001</year><volume>91</volume><fpage>863</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11241256</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>McCarron</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>The changing global patterns of female breast cancer incidence and mortality</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><fpage>229</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">15535852</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>AH</given-names></name><name><surname>Bihrmann</surname><given-names>K</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Vejborg</surname><given-names>I</given-names></name><name><surname>Lynge</surname><given-names>E</given-names></name></person-group><article-title>Breast density and outcome of mammography screening: a cohort study</article-title><source>Br J Cancer</source><year>2009</year><volume>100</volume><fpage>1205</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19293800</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Cairns</surname><given-names>BJ</given-names></name><name><surname>Casabonne</surname><given-names>D</given-names></name><name><surname>Wright</surname><given-names>FL</given-names></name><name><surname>Reeves</surname><given-names>G</given-names></name><name><surname>Beral</surname><given-names>V</given-names></name></person-group><article-title>Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk</article-title><source>Lancet Oncol</source><year>2011</year><volume>12</volume><fpage>785</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">21782509</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>Y</given-names></name><name><surname>Hai</surname><given-names>E</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers</article-title><source>Int J Clin Oncol</source><year>2008</year><volume>13</volume><fpage>431</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18946753</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elebro</surname><given-names>K</given-names></name><name><surname>Butt</surname><given-names>S</given-names></name><name><surname>Dorkhan</surname><given-names>M</given-names></name><name><surname>Jernstrom</surname><given-names>H</given-names></name><name><surname>Borgquist</surname><given-names>S</given-names></name></person-group><article-title>Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmo Diet and Cancer Cohort</article-title><source>Cancer Causes Control</source><year>2014</year><volume>25</volume><fpage>945</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">24825327</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irigoyen</surname><given-names>MA</given-names></name><name><surname>Garcia</surname><given-names>FV</given-names></name><name><surname>Iturriagagoitia</surname><given-names>AC</given-names></name><name><surname>Beroiz</surname><given-names>BI</given-names></name><name><surname>Martinez</surname><given-names>MS</given-names></name><name><surname>Grima</surname><given-names>FG</given-names></name></person-group><article-title>Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics</article-title><source>An Sist Sanit Navar</source><year>2011</year><volume>34</volume><fpage>219</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21904404</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehdi</surname><given-names>I</given-names></name><name><surname>Monem</surname><given-names>AA</given-names></name><name><surname>Al Bahrani</surname><given-names>B</given-names></name><name><surname>Ramadhan</surname><given-names>FA</given-names></name></person-group><article-title>Breast cancer molecular subtypes in Oman: correlation with age, histology, and stage distribution &#x02013; analysis of 542 cases</article-title><source>Gulf J Oncolog</source><year>2014</year><volume>1</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">24610287</pub-id></element-citation></ref></ref-list></back></article>